Shares of Grail, Inc. (NASDAQ:GRAL - Get Free Report) were down 3.6% during mid-day trading on Tuesday . The company traded as low as $30.19 and last traded at $30.97. Approximately 128,782 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 1,224,569 shares. The stock had previously closed at $32.13.
Analysts Set New Price Targets
Separately, Morgan Stanley upped their target price on Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a report on Tuesday, March 18th.
Get Our Latest Analysis on Grail
Grail Stock Performance
The business's 50-day moving average is $34.03 and its 200-day moving average is $22.35.
Grail (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The firm had revenue of $38.25 million for the quarter, compared to the consensus estimate of $35.33 million. As a group, equities analysts anticipate that Grail, Inc. will post -15.15 earnings per share for the current year.
Insiders Place Their Bets
In related news, CFO Aaron Freidin sold 1,816 shares of the firm's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $56,659.20. Following the transaction, the chief financial officer now directly owns 335,170 shares of the company's stock, valued at approximately $10,457,304. This trade represents a 0.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Ragusa sold 7,625 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.21, for a total value of $237,976.25. Following the transaction, the chief executive officer now owns 828,662 shares of the company's stock, valued at approximately $25,862,541.02. This trade represents a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,550 shares of company stock valued at $360,436.
Institutional Trading of Grail
Hedge funds have recently bought and sold shares of the stock. FNY Investment Advisers LLC bought a new position in Grail during the fourth quarter valued at approximately $26,000. State of Tennessee Department of Treasury bought a new stake in Grail in the fourth quarter worth $28,000. Lindbrook Capital LLC purchased a new stake in Grail during the fourth quarter valued at $28,000. Sterling Capital Management LLC bought a new position in Grail during the fourth quarter valued at $29,000. Finally, Wellington Shields Capital Management LLC purchased a new position in shares of Grail in the 4th quarter worth $33,000.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Stories
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
